Bank of America’s $250M Weight Loss Drug Bet: Wellness, Costs, and the Shifting Tides of Corporate Healthcare

(SeaPRwire) –   By: Christian Pierce

In the ever-evolving landscape of corporate healthcare, Bank of America has thrown down the gauntlet with a bold move: shelling out a whopping $250 million annually on weight loss drugs for its employees. This isn’t just a financial decision; it’s a strategic wager on the well-being of its workforce, one that CEO Brian Moynihan believes will yield significant dividends.

Weight loss drugs have skyrocketed in popularity as an employee perk, with nearly a third of workers stating they’d switch jobs for GLP-1 coverage. Bank of America’s substantial investment is part of a broader $2 billion annual wellness package for employee healthcare at the $436 billion bank. While staffers may need to cover part of the cost, the bank is footing the majority of the bill, amounting to nearly a quarter of a million dollars per year.

Moynihan’s conviction in this investment stems from the tangible impact he’s witnessed. “What we see is a great impact on the employees,” he recently told CNBC. “We’ve always been about mental wellness, physical wellness.” He pointed out that the drugs are already showing benefits in reducing near-term incidents of heart issues for those taking them, even without all the typical risk factors. “That’s the payback,” he said.

The chief executive also acknowledges that the bank might not fully reap all the long-term benefits. Some employees on GLP-1s may not experience the health upsides until later in life, after leaving the company. However, he remains steadfast in his belief that it’s the right thing to do for his teammates. “We do it because we want to be the great place to work,” Moynihan said. “It’s been fascinating to watch our teammates’ behavior on these adjustments, the loss of weight. We monitor that, we give them coaches and everything, and so it’s a good investment by us.”

But Bank of America isn’t alone in this healthcare conundrum. Across the corporate world, weight loss drugs are causing ripples. In the past couple of years, medications like Ozempic, Wegovy, and Zepbound have exploded onto the wellness market. GLP-1s, originally developed to manage blood sugar levels in type 2 diabetes patients, have become a staple in millions of Americans’ lives. Around 11% of U.S. adults currently take GLP-1 medications for weight loss, a significant jump from just 3% two years ago, according to a recent Gallup analysis.

As a result, companies are scrambling to adapt their health offerings. While 60% of employers said they offer GLP-1 coverage solely for diabetes, around 36% also cover it for both diabetes and weight loss. Earlier this year, consulting giant PwC announced it would no longer cover GLP-1s as an employee benefit for weight loss alone, citing “rapidly rising costs.” Instead, the drug would only be available when prescribed for conditions like type 2 diabetes, aligning with established standards of care.

The cost factor is a double-edged sword. On one hand, GLP-1s have become more affordable due to high demand, manufacturer price cuts, direct-to-consumer options, and new government programs. A starting dose of Wegovy now costs just $149 a month, down from $1,600 a month when it launched in the U.S. in 2021. Amazon One Medical’s GLP-1 management program offers insured individuals the drugs for as little as $25 a month.

On the other hand, soaring demand and long-term use are putting employers in a financial bind. More than a quarter of large corporations are tightening GLP-1 coverage criteria in 2026 or 2027, according to a Mercer analysis. Around 11% of these big employers have already dropped or are planning to drop coverage for weight loss this year or next.

Health services company Cigna stopped covering GLP-1 weight loss drugs like Wegovy and Zepbound in its employee health plan this July. The company cited increased availability and new options as the reason, but assured staffers they still have access to weight management programs and resources. HCA Healthcare, which employs hundreds of thousands of workers across its hospitals and medical centers, halted coverage for weight loss in January after a 90% spike in GLP-1 use on its employee plan in 2025 alone. It still covers the drug for diabetes.

This trend highlights the delicate balance companies must strike between attracting and retaining top talent with competitive benefits and managing the escalating costs of healthcare. Bank of America’s decision to invest heavily in weight loss drugs for its employees signals a growing recognition of the importance of employee well-being in the workplace. However, as other companies grapple with the financial implications, it remains to be seen how this trend will evolve in the coming years.

Author bio: Christian Pierce, a chief financial columnist and markets commentator, closely follows corporate financial strategies and healthcare trends.